Document Detail

Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients.
MedLine Citation:
PMID:  10456618     Owner:  NLM     Status:  MEDLINE    
Lipid-lowering therapy reduces cardiac events to an extent that is disproportionate to the small degree of regression of coronary atherosclerosis observed among hyperlipidemic patients. We prospectively investigated the effects of lipid reduction using simvastatin on the endothelial dysfunction and hypercoagulability found in hyperlipidemic patients. We measured levels of coagulation factors [factor VII (FVII) coagulant activity (FVIIc), FVII antigen (FVIIAg), activated FVII (FVIIa), and fibrinogen], and markers of coagulation activation [prothrombin fragment 1 + 2 (F1 + 2)] and endothelial cell dysfunction [von Willebrand factor (vWF)] in 20 hyperlipidemic patients, 20 hypertensive patients, and 20 normotensive normolipidemic controls. The levels of FVIIa, FVIIc, FVIIAg, F1 + 2, and vWF were all higher in hyperlipidemic patients, but only FVIIa, F1 + 2, and vWF levels were higher in hypertensive patients than in controls. We measured the above parameters in 13 hyperlipidemic patients before and after 1, 3, 6, 12 and 24 months of simvastatin therapy and compared these values with those in 15 hypertensive patients at baseline and after 12 and 24 months. The median (25th-75th percentile) level of total cholesterol was decreased from 259 (255-278) to 206 (176-220) mg/dl after 1 month of simvastatin therapy and this reduction persisted for 2 years. The plasma level of vWF [136% (113-158%)] was not changed after 1 month of administration of simvastatin [132% (115-153%)], but was decreased after 3 months of treatment [114% (96-128%), P<0.01]. This decrease also persisted for 2 years during simvastatin therapy and both of these reductions were significant, compared with levels in hypertensive patients. In contrast, levels of fibrinogen, FVIIc, FVIIAg, FVIIa, and F1 + 2 did not change throughout the 2 years of simvastatin therapy. We conclude that lipid reduction using simvastatin corrects endothelial cell dysfunction but not hypercoagulability in hyperlipidemic patients. The improvement in endothelial cell function brought about by lipid-lowering therapy might contribute to the reduction in cardiac events within a relatively short time period in hyperlipidemic patients.
K Kario; T Matsuo; S Hoshide; H Kobayashi; T Sakata; O Mizuno; T Mitsuhashi; U Ikeda; T Miyata; K Shimada
Related Documents :
22882428 - Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis...
21996048 - Use of mean spot urine sodium concentrations to estimate daily sodium intake in patient...
22331168 - Influence of the side of brain damage on postural upper-limb control including the scap...
22871678 - Continuous stroke unit electrocardiographic monitoring versus 24-hour holter electrocar...
1901108 - Liver function tests in patients receiving parenteral nutrition.
2545768 - Bilateral and simultaneous venous sampling of inferior petrosal sinuses for acth and pr...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  10     ISSN:  0957-5235     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  1999 Jul 
Date Detail:
Created Date:  1999-09-21     Completed Date:  1999-09-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  269-76     Citation Subset:  IM    
Department of Cardiology, Jichi Medical School, Tochigi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antilipemic Agents / pharmacology*,  therapeutic use
Blood Coagulation / drug effects*
Endothelium, Vascular / drug effects*,  physiopathology
Hyperlipidemias / blood,  drug therapy*,  physiopathology
Lipid Metabolism
Simvastatin / pharmacology*,  therapeutic use
Time Factors
Reg. No./Substance:
0/Antilipemic Agents; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Alterations to the fibrinolytic enzyme system in patients with non-small cell lung carcinoma.
Next Document:  Soluble intercelluar adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Will...